785 Old Saw Mill Rd
15 articles with Regeneron
Ultima Genomics signs development agreement with Regeneron aimed at driving the scale of genomic information for drug discovery and development
Ultima Genomics, Inc. (the Company) has signed an agreement with Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) to further advance Ultima Genomics' sequencing architecture.
BioNTech and Regeneron Expand Strategic Collaboration to Advance Clinical Development of FixVac and Libtayo® (cemiplimab) Combination in NSCLC
BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today announced the expansion of its strategic collaboration with Regeneron to advance the Company’s FixVac candidate BNT116 in combination with Libtayo® (cemiplimab), a PD-1 inhibitor, in advanced non-small cell lung cancer (NSCLC).
Decibel Therapeutics Announces Extension of Research Term under Strategic Collaboration with Regeneron to Discover and Develop Gene Therapies for Hearing Loss
Decibel Therapeutics today announced that Regeneron has extended the research term of its collaboration with the Company to discover and develop gene therapies for hearing loss.
Second Dupixent® (dupilumab) Phase 3 eosinophilic esophagitis trial to demonstrate significant disease improvements, underscoring role of type 2 inflammation in this complex disease
Results from a second Phase 3 trial assessing the investigational use of Dupixent® in patients 12 years and older with eosinophilic esophagitis demonstrated that the trial met its co-primary endpoints in patients taking Dupixent 300 mg weekly, showing significant improvements in clinical and histologic disease measures compared to placebo.
Dupixent® (dupilumab) pivotal trial meets all primary and secondary endpoints becoming first biologic medicine to significantly reduce signs and symptoms of moderate-to-severe atopic dermatitis in children as young as 6 months
A pivotal Phase 3 trial evaluating Dupixent® for the treatment of children aged 6 months to 5 years with moderate-to-severe atopic dermatitis, a chronic type 2 inflammatory disease, met its primary and all secondary endpoints.
Dupixent® (dupilumab) SmPC updated with long-term data reinforcing well-established safety profile in adults with moderate-to-severe atopic dermatitis
Long-term safety data from a study of adults with moderate-to-severe atopic dermatitis treated with Dupixent will be added to the Dupixent Summary of Product Characteristics following a positive opinion issued by the European Medicines Agency’s Committee for Medicinal Products for Human Use.
American Diabetes Association, with Visionary Partners VSP Vision Care and Regeneron Launch "The Next Step Eye Challenge" Campaign for Healthy Vision Month in May
Over 34 million American adults currently live with diabetes and an additional 88 million are living with prediabetes, yet 85% of them do not know they have it.
The Series A rounds are the latest in a string of financing announcements made over the past few months.
BioNTech Announces Strategic Collaboration with Regeneron to Advance FixVac and Libtayo® (cemiplimab) Combination in Melanoma
BioNTech and Regeneron plan to jointly conduct a randomized Phase 2 study combining BNT111 FixVac and Libtayo for the treatment of melanoma that has progressed after prior PD-1 blockade
New Genetic Data from Regeneron and GSK on 50,000 UK Biobank Participants Made Available to Global Health Research Community
Represents first tranche to be released; data from all 500,000 UK Biobank participants will ultimately be made available via larger biopharma consortium effort
This is the latest step by the companies to help make Praluent more accessible and affordable for appropriate patients
New England Journal of Medicine publishes positive detailed results from Praluent® (alirocumab) Injection cardiovascular outcomes trial
Praluent significantly reduced major adverse cardiovascular events by 15% (p<0.001)
FDA to Conduct Priority Review of Cemiplimab as a Potential Treatment for Advanced Cutaneous Squamous Cell Carcinoma
The U.S. Food and Drug Administration (FDA) has accepted for priority review the Biologics License Application (BLA) for cemiplimab for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or patients with locally advanced CSCC who are not candidates for surgery.
Geisinger Health System: Gene variant that protects against chronic liver disease found using MyCode data
Scientists at the Regeneron Genetics Center, along with investigators at Geisinger, have discovered a gene variant associated with a significant reduction in the risk for chronic liver disease, according to study findings released today in the New England Journal of Medicine.
Although the stock market seems to be moving up at the beginning of this year, the U.S. equities market appears more mixed, with healthcare stocks in particular appearing more volatile.